1789 Stock Overview
Research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ScinoPharm Taiwan, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.20 |
| 52 Week High | NT$30.50 |
| 52 Week Low | NT$16.50 |
| Beta | 0.36 |
| 1 Month Change | 4.92% |
| 3 Month Change | -15.42% |
| 1 Year Change | -30.43% |
| 3 Year Change | -14.48% |
| 5 Year Change | -39.05% |
| Change since IPO | -56.41% |
Recent News & Updates
Recent updates
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 17
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Shareholder Returns
| 1789 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 2.1% | 0.2% | 1.4% |
| 1Y | -30.4% | -14.2% | -2.0% |
Return vs Industry: 1789 underperformed the TW Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: 1789 underperformed the TW Market which returned -2% over the past year.
Price Volatility
| 1789 volatility | |
|---|---|
| 1789 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in TW Market | 10.2% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 1789 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1789's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Susan Lu | www.scinopharm.com |
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates, as well as develops peptide synthesis technologies.
ScinoPharm Taiwan, Ltd. Fundamentals Summary
| 1789 fundamental statistics | |
|---|---|
| Market cap | NT$15.18b |
| Earnings (TTM) | NT$245.35m |
| Revenue (TTM) | NT$3.21b |
61.9x
P/E Ratio4.7x
P/S RatioIs 1789 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1789 income statement (TTM) | |
|---|---|
| Revenue | NT$3.21b |
| Cost of Revenue | NT$2.03b |
| Gross Profit | NT$1.17b |
| Other Expenses | NT$929.54m |
| Earnings | NT$245.35m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 36.61% |
| Net Profit Margin | 7.64% |
| Debt/Equity Ratio | 0.5% |
How did 1789 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield112%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 02:24 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ScinoPharm Taiwan, Ltd. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ti-Rung Huang | Barclays |
| Christine Wang | Daiwa Securities Co. Ltd. |
| John Chou | Deutsche Bank |